Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy

Executive Summary

NEW DELHI - Abbott is set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare May 21

You may also be interested in...



In 2012, Pfizer’s Deal-Makers Seek Strategic Fit, Financial Discipline, Collaborative Risk-Sharing

The Big Pharma has the global scale and reach it needs, but will fill in gaps with deals in which it can add “a lot of” scientific value and “incremental” commercial value, says Pfizer’s EVP-Business Development Kristin Peck.

Abbott Shaves U.S. Pharma Costs With Restructuring

Abbott plans to eliminate 1,900 positions, mainly within commercial and manufacturing, in a restructuring that will yield pre-tax savings of $200 million.

More Deal Of The Year Nominees

It's time for The IN VIVO Blog's Third Annual Deal of the Year competition. This year, awards will be presented in three categories to highlight the most interesting and creative deal making solutions of 2010.

Related Content

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel